3rd Quarter 2009 Report

(Thomson Reuters ONE) - Oslo, Norway, 27 October 2009.Please find attached the third quarter report 2009 for PCI BiotechHolding ASA.Kind regards,Per WaldayCEOEmail: pw(at)pcibiotech.noMobil: +47 917 93 429http://hugin.info/139147/R/1350200/325656.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 27.10.2009 - 08:01 Uhr
Sprache: Deutsch
News-ID 7440
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 220 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"3rd Quarter 2009 Report"
steht unter der journalistisch-redaktionellen Verantwortung von

PCI Biotech Holding (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Can ...

PCI Biotech has initiated pre-clinical trials for the use of Photochemical Internalisation (PCI) in the treatment of Bladder cancer. The pre-clinical trials will be concluded during the first half of 2010, and a phase I/II study (first in man) is exp ...

PCI Biotech - Financial calendar for 2010: ...

19 February 2010 - Presentation of the fourth quarter 2009 report 27 April 2010 - Presentation of the first quarter 2010 report 27 April 2010 - Annual General Meeting 24 August 2010 - Presentation of the second quarter 2010 report 26 October 2010 - P ...

Successful completion of the first dose group in the Phase I/II study of Amphine ...

Oslo, 19 October 2009 - PCI Biotech has completed the treatment of the first dose group in the phase I/II study of Amphinex® in cancer patients. No serious adverse events have been recorded and tumour response was seen even at this low dose. The stu ...

Alle Meldungen von PCI Biotech Holding